Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 18/20 | 0.60 |
| ▸ | CASP7 | P55210 | 2/20 | 0.59 |
| ▸ | CASP9 | P55211 | 2/20 | 0.59 |
| ▸ | CASP6 | P55212 | 2/20 | 0.59 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26071633 | 1.00 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL4466395 | 1.00 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL24213871 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL17494194 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL14646635 | 0.96 | CASP3 (0.56) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL29043505 | 0.91 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL30376490 | 0.91 | CASP3 (0.57) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL8353502 | 0.90 | CASP3 (0.55) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL23268995 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 | |
| SCHEMBL23269036 | 0.90 | CASP3 (0.60) | CASP3CASP7CASP9CASP6CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | LG CHEM, LTD. (KR) | 2023-10-05 | — | — | US | claimed |
| CN-116113413-A | Use of caspase inhibitors for the alleviation or treatment of osteoarthritis | 株式会社LG化学 | 2023-05-12 | — | — | CN | claimed |
| EP-4173622-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | Lg Chem, Ltd. (KR) | 2023-05-03 | — | — | EP | claimed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | claimed |
| WO-2022030987-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | 주식회사 엘지화학 | 2022-02-10 | — | — | WO | claimed |
| US-20260117095-A1 | FOAM SHEET AND ADHESIVE TAPE | SEKISUI CHEMICAL CO., LTD. (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4499350-B1 | GRIPPER UNIT, GRIPPER SYSTEM, AND METHOD OF GRIPPING AN OBJECT | SONY GROUP CORP (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260070024-A1 | Asymmetric Hollow Fiber Membrane | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4651244-A1 | FILM AND REINFORCEMENT MEMBER FOR ELECTROLYTE MEMBRANES OF POLYMER ELECTROLYTE FUEL CELLS USING SAME | Toyobo Co., Ltd. (JP) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025109964-A1 | CURABLE COMPOSITION AND CURED PRODUCT | 株式会社カネカ | 2025-05-30 | — | — | WO | disclosed |
| CN-119856253-A | Base film for semiconductor manufacturing tape | 日本他喜龙希爱株式会社 | 2025-04-18 | — | — | CN | disclosed |
| CN-119816924-A | Base film for semiconductor manufacturing tape | 日本他喜龙希爱株式会社 | 2025-04-11 | — | — | CN | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | disclosed |
| CN-114456748-A | Adhesive composition and self-adhesive protective film | 张家港康得新光电材料有限公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2022091960-A1 | LAYERED FILM AND COPPER-CLAD LAYERED SHEET | 株式会社カネカ | 2022-05-05 | — | — | WO | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| WO-2022054887-A1 | MULTILAYER STRUCTURE AND PACKAGING CONTAINER COMPRISING SAME | 株式会社クラレ | 2022-03-17 | — | — | WO | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
| WO-2022030987-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | 주식회사 엘지화학 | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310412-A1 | USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITIS | CASP1, CASP2, CASP5 | CASP3 6/4885CASP7 10/4885CASP9 12/4885 |
| US-20260070024-A1 | Asymmetric Hollow Fiber Membrane | CUTA, CD68, DSG1 | CASP3 2055/4885CASP7 809/4885CASP9 2620/4885 |
| US-20260117095-A1 | FOAM SHEET AND ADHESIVE TAPE | CFL1, TIAL1, PFN1 | CASP3 2551/4885CASP7 1828/4885CASP9 2457/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CASP3 1001/4885CASP7 1102/4885CASP9 652/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | CASP3 773/4885CASP7 844/4885CASP9 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.